Where is Enasidenib 60 tablets produced?

Enasidenib (Enasidenib), developed by Celgene Corporation (now Bristol-Myers Squibb), is the first oral targeted mutant isocitrate dehydrogenase 2 (IDH2) inhibitor for the treatment of ID Patients with relapsed or refractory acute myeloid leukemia (AML) with H2 mutations. Ensidipine is supplied as the mesylate salt, which is available for oral administration in 50 mg tablets (equivalent to 60 mg Enasidenib) and 100 mg tablets (equivalent to 120 mg Enasidenib).

A protein called isocitrate dehydrogenase2, often called "IDH2," can mutate in immature bone marrow white blood cells. Mutated IDH2 proteins can prevent these cells from maturing into normal functioning cells and cause their accumulation to lead to acute myeloid leukemia (AML). Ensidipine is designed to bind to the mutated IDH2 protein in myeloid leukemia cells. By blocking the function of the mutated IDH2 protein, ensidipine allows cells to mature normally. Patients without known IDH2 mutations may not benefit from ensidipine.

Encidipine research medicine is not currently on the market in China, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad. For more information on overseas drug prices and specific information, please consult Yaode Medical Consultant.